Inhibikase Therapeutics, Inc. (IKT) Marketable Securities, Current USD 2021 - 2024

Historical data

Taxonomy & unit: us-gaap: USD
Description: Amount of investment in marketable security, classified as current.
Summary: Inhibikase Therapeutics, Inc. quarterly Marketable Securities, Current history and growth rate from 2021 to 2024.
Inhibikase Therapeutics, Inc. Marketable Securities, Current for the quarter ending March 31, 2024 was $7.4 M, a 66% decline year-over-year.

Marketable Securities, Current, Quarterly (USD)

Marketable Securities, Current, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date	Report	Filed
Q1 2024	$7.4 M	-$14.4 M	-66%	Mar 31, 2024	10-Q	2024-05-15
Q4 2023	$4.09 M	-$11.8 M	-74.2%	Dec 31, 2023	10-Q	2024-05-15
Q3 2023	$1.97 M	-$18.8 M	-90.5%	Sep 30, 2023	10-Q	2023-11-14
Q2 2023	$19 M			Jun 30, 2023	10-Q	2023-08-14
Q1 2023	$21.8 M			Mar 31, 2023	10-Q	2023-05-15
Q4 2022	$15.9 M	+$15.9 M		Dec 31, 2022	10-K	2024-03-27
Q3 2022	$20.8 M			Sep 30, 2022	10-Q	2022-11-14
Q4 2021	$0			Dec 31, 2021	10-K	2023-03-31

* An asterisk sign (*) next to the value indicates that the value is likely invalid.